Table of contents
At a glance
What matters when validating Opcenter Execution Pharma?
Demonstrate that approved MBR and EWI instructions are executed and recorded correctly through the clients and automation paths in use. For release 2605, distinguish supported web scenarios from those that still require the existing client. Test roles, handovers, exceptions and the meaning of the results. An available feature does not establish that all paths behave identically or that the local configuration is suitable.
- Refer each statement to Opcenter Execution Pharma and the deployed system.
- Establish a technically justified execution pathway that is actually supported.
- Verify equipment release, process result, and batch record separately.
- Treat new clients and routes as specific change and documentation questions.
1. Scope of Opcenter Execution Pharma and Release 2605 to be defined
Opcenter Execution Pharma is the pharmaceutical MES within the Siemens product portfolio. The manufacturer's description integrates Master Batch Records (MBR) with both manual and automated execution, as well as electronic batch records. Other Opcenter lines do not serve as a substitute for the same functionality or configuration.
The Siemens blog post dated 15 June 2026 describes Opcenter EX PH 2605. This version-specific document serves as the basis for this article, not as evidence of the latest patch. The general product page complements the classification of MBR, production control, and exception checking.
Capture in the project the application version in use, associated clients, device integrations, and local enhancements. Clarify which functions are actually licensed, provided, and supported. A release description outlines available options, but does not include a ready-to-use configuration for your facility.
The regulatory focus is on human medicinal product GMP. Annex 11 and Chapter 4 are used as GMP guidelines in their current version. Manufacturer formulations for compliance are not accepted as evidence of the suitability of your manufacturing process.
2. From the MBR to the executable work instruction
Siemens describes a MBR-controlled manufacturing process and electronic work instructions, or EWI. For practical verification, the specification, executable logic, and actually generated records must be consistent. A technically accurate description is insufficient if its implementation deviates significantly from the intended technical approach.
Therefore, compare the released instruction with the required inputs, conditions, and transitions. Which value is manually entered, which is transferred from a device, and which is generated by calculation? Who is authorized to use a special route, and what criteria does the subsequent step use to verify its prerequisites?
Maintain records of the actually used containers. In subsequent reviews, it must be clearly evident which instruction applied to the respective order. A previously amended template must not be issued as justification for an older process.
The tables in this guide are intended as planning aids. They translate the general requirement for traceable documentation into specific implementation approaches, without prescribing an official MBR format or a universal EWI structure.
3. Web-EWI and weighing application differ based on actual coverage
For 2605, Siemens provides additional web-based EWI functions for list, label, and barcode identification, as well as warning messages. The release note also includes enhancements regarding electronic signatures and access rights management. It is to be verified at the respective site which of these features supports your specific workflow.
Siemens describes a modular architecture for web-based weighing and dispensing, featuring predefined weighing steps and Manual and Net modes. Scale communication is specified via Mendix workstation. This does not imply universal support for every scale, every browser, or every process variant.
The particularly significant boundary is explicitly stated in the release documentation: the web application is available for supported cases in 2605; the existing rich client remains available for more advanced or currently unaddressed scenarios. Therefore, web and legacy client applications are not automatically functionally equivalent.
Request a specific coverage statement for your cases. A roadmap or the possibility of future expansion is not a currently available feature. Only plan a productive path once its prerequisites and supporting evidence have been established.
4. Example: filled matrix for a production order
The following example was not executed in Opcenter. Order A-17 uses MBR M3 and work instruction E6. It includes identification, weighing, an automated mixing step, and a final review. The version names and test levels are example identifiers.
For the normal weighing scenario, local support of Web mode NET is planned as a required condition. An alternative special procedure SV1 will remain assigned to the existing procedure until specific client coverage is demonstrated. No specific special function of a Siemens client is claimed.
The matrix indicates which documents and procedures are required to support each respective pathway. The named tests W-01 to W-05 are planned validations, not completed tests. If a prerequisite is not met, the corresponding statement remains open.
| Technical step and instruction | Intended Route and Transfer | Expected recordkeeping | Evidence of what is covered |
|---|---|---|---|
| A10: Identify container B-17 according to E6 | Web-EWI with barcode function, provided local setup is available | Order, recognized container identification and result of assignment | W-01: B-17 is correctly assigned; foreign B-71 follows the defined error path |
| A20: record the nominal net value | Web Scales, Mode Net; approved scale integration via local workstation | Value, unit, balance and reference to A-17 | W-02: Device data and MES logging are consistent during the agreed-upon test |
| SV1: additional customer-specific weighing procedure | Existing procedure; Rich-client support separately allocated, no web parity assumed | Evidence according to the specified special instruction | W-03: Fully evaluate variant; missing coverage remains open |
| A30: Perform defined mixing phase | MES handover to production control; local coupling separately specified | Requirement, associated feedback and actual process status | W-04: Receipt without confirmed process start does not result in false closure |
| A40: Technically review the request | Fixed review view including relevant exceptions | A continuous batch history linking the specified requirements to the findings | W-05: Web, inventory traceability, and automation data are accurately consolidated. |
5. Evaluate the client path with a specific failure scenario
For W-01, B-17 is first identified. The test expects assignment to the order A-17. Subsequently, the foreign identifier B-71 is deliberately used. Which result is acceptable follows the example requirement: a wrong assignment must not be silently recorded as a correct identification.
For W-02, predefined test values are used independently: Gross weight 3.250 kg, tare 0.750 kg, resulting in net weight 2.500 kg. The calculation 3.250 minus 0.750 equals 2.500 is a standalone test specification and does not represent any specific internal Siemens computation. Verify that the actually accepted value and its significance are consistent with the established measurement chain.
The communication path defined for the test is interrupted prior to the required confirmation. The pre-specified behavior, including a clearly detectable open state, is expected. A previously visible old value must not be considered a new successful entry without prior verification. It is to be separately determined whether your facility retains values in interim storage.
The team must not subsequently simply defer to the other client and consider the step as completed. First, validation evidence for an appropriate transition, common procedural linkage, and resolution of the open state must be provided. Without this coverage, the transition remains unvalidated for this scenario.
6. Automation: View command, confirmation, and process result separately
Siemens defines the integration with production control as well as the management of manual and automated steps. For local validation, you still require a clear interface specification. What requirements does the MES transmit, what feedback is returned, and what is its significance?
In example step A30, a technical receipt confirmation may already be available, even though the desired process start has not been confirmed. The appropriate validation question then becomes whether the system takes into account this distinction in its subsequent processing. A green communication signal alone would not constitute evidence of the intended outcome.
In addition, verify assignment to order, attachment, and step. A delayed response from the previous step must not go unnoticed and be incorporated into the current process without review. Identify such cases based on the actual integration architecture; the public product documentation neither specifies your message format nor your error handling approach.
The inspection does not end at the screen boundary. Equipment or automation records and MES documentation must be able to explain the same sequence of events. This is particularly important when different systems use different time stamps or status definitions.
7. Introduce new pathways with a clear decision on adoption
An available web step may alter the workflow without covering all existing cases. Therefore, clearly document which statements from prior validations remain valid and which new assumption is introduced by the change. The table below serves as a standalone decision support tool for planning.
Distinguish a change for future orders from a change during an open process. The second case raises additional questions regarding stored states, authorization, and continuation. A successful evaluation of the first case does not automatically validate the second.
| Change in the example | Check if the statement remains usable. | New question to be answered | Planned decision |
|---|---|---|---|
| A10 future via Web-EWI instead of the previous route | Professional designation rules remain unchanged | Correct display, identification, and error response in the web environment? | W-01 plus appropriate access review prior to takeover |
| A20 future via Web-Net-mode | Netto value and unit remain the same | Local device/workstation chain and adequate data capture? | W-02 at the actual path; no blanket reference to Rich-Client Testing |
| SV1 should also be included in the web | Approved special release remains the professional basis. | Is SV1 supported in this state? | No web takeover planning without positive coverage evidence |
| Change during open A20 | Already performed partial steps are identifiable | Which data are stored in a binding manner, how is continued? | Specify separate swap and interruption cases |
| A30 receives updated feedback | Unchanged operational functions may continue to apply | Is the status significance and order assignment correct? | Review W-04 and related follow-up inspections anew |
8. Review and signatures are linked to the complete execution
The manufacturer's description references a review by exception and central batch records. Specify which information a reviewer needs for your process. In the example, this includes the used instruction, the identification method, the weighing record, and the automation feedback together with relevant findings.
Assess the scope of the exception rules. An event may be accurately recorded yet not appear in the selected view. An empty display only conveys a relevant statement if its data foundation and detection logic are appropriate for the intended review.
The signature extensions described in 2605 are functional information. They do not replace assessment of authorized action, identity, relevance, and linkage to the relevant record. Annex 11, Section 14, outlines requirements for electronic signatures in the applicable GMP context.
In addition, distinguish between technical qualification, professional review, and, if applicable, required batch certification. A status change in the MES is not solely evidence that each of these decisions was made by the authorized responsible person.
9. Resource allocation, supplier documentation, and operations planning for SMEs
The scope arises from the number of actually distinct process configurations, their respective device chains, and the required dedicated pathways. Two workstations performing the same process may require different validation evidence if only one employs a different weighing system integration or a separate expansion module.
For preparation, you will need a subject-matter expert responsible for MBR/EWI, a point of contact for automation and equipment, as well as responsibilities for IT operations and quality assessment. The manufacturer or partner may provide technical documentation. However, process decisions and the suitability of local implementation require specific contributions from your team.
Align the statements in a manufacturer's report with the respective internal requirements. What does it already demonstrate, and which process steps or interfaces are missing? From this comparative assessment, targeted supplements—along with associated effort and responsibility—can be planned.
Following changes, also consider historical records, restoration capabilities, and availability. The previous batch history must remain retrievable through the intended pathway. Additionally, clarify the operating model, licensing scope, and required internal resources for your specific implementation.
10. Checklist for Opcenter Implementation Paths
Use the following worksheet to make a proposed approach specifically verifiable. Document both open points and deliberately excluded alternatives. This will clearly demonstrate the actual scope of the validation planning.
- Product line, release, patch, and deployed clients are identified.
- The MBR-/EWI-status is associated with the current competent technical instruction.
- Every relevant step has an actually supported execution pathway.
- Web and inventory client coverage are not to be equated arbitrarily.
- Device, workstation, value meaning, and unit are defined and clarified for weighing operations.
- Technical release and business process outcome are distinguishable.
- Interruption and substitution of an ongoing process are evaluated separately.
- Review view and signature context capture the required information.
- Supplier documentation and local amendments have a traceable assignment.
- Operation, modifications, and access to prior batch records are governed.
Project experience and collaboration
Test the manufacturing workflow across clients and handovers
With Manufacturing, QA and IT, we connect an approved instruction to a prepared execution step in Opcenter, following the client used, transferred values and resulting record. Manufacturer documentation may cover demonstrated standard functions. Local automation paths and exceptions need appropriate additional evidence. Different interfaces may present information differently, but each must deliver the result defined for its use. We help the teams agree who supplies each test and who makes each decision.
Frequently asked questions about Opcenter Execution Pharma
Does this guidance apply to all Siemens Opcenter products?
No. The functional evidence relates to Opcenter Execution Pharma, specifically the vendor contribution to Release 2605. Other Opcenter lines, additional applications, or older versions require separate delineation. Keep track of the actually used components within the project. The shared portfolio label is not a validation of identical MBR-, weighing-, or client functionalities.
Are the web application and the previous client application fully equivalent for batch 2605?
This does not provide a general description of Siemens for scale weighing applications. A web-based version is available for supported cases; the existing rich client remains available for more advanced or currently unaddressed scenarios. Therefore, please verify your specific configuration. An announced enhancement in future releases must not be assumed to be already implemented in the currently deployed version.
Sources: [2]
Which web weighing functions are described as publicly available for 2605?
The release document outlines a modular framework, including predefined steps for material selection, scale interaction, execution, and label printing, as well as manual and net-as-mode options. Scale communication is described via Mendix Workstation. These descriptions do not constitute a review or validation of supported hardware, configuration, or local variants. In particular, this does not imply complete coverage of all previous rich-client scenarios.
Sources: [2]
Can an ongoing process continue in another client after a failure?
Only a specifically documented and permissible for your workflow transition qualifies this decision. Clarify the stored state, procedural context, and handling of open confirmations. This guide does not assert a general seamless handover between clients. Passing a review of a newly initiated web order does not automatically serve as evidence for the continuation of an interrupted existing process.
What additional responsibilities must the MBR/EWI review perform beyond text checking?
She must consider the connection to the actually executable logic and to the generated evidence. Verify required inputs, conditions, roles, device values, and transitions. A correctly formulated instruction may be technically implemented differently. It must also remain clearly identifiable at a later stage which version executed the task. The specific execution pathway matrix helps assign these questions step by step.
Does a successful DCS clearance serve as evidence of completion of a production step?
Not without clear definition. Approval may, for example, only confirm the receipt of a request. Verify which feedback is actually documented by the process execution and how it is properly linked to the intended instruction. In the example of this article for instruction A-17, receipt shall not be considered the completion of a mixing phase. The exact interface mechanics must emerge from your local specification and supporting evidence.
Does a Review by Exception replace the need to examine the data foundation?
No. A suitable exception process requires a robust identification and the appropriate underlying records. Determine which rules and data pathways are relevant to your review, and assess their coverage. The scope and timing of the subsequent evaluation follow the process. An empty list alone neither confirms completeness of data capture nor validates the suitability of any batch release decision.
Are the described electronic signatures sufficiently adequate for our GMP process?
The manufacturer function serves as a starting point for the specific evaluation. It must be established whether the action is authorized, the responsible individual is identified, and there is a lasting link to the relevant record. The significance of confirmation must be clearly understood within the workflow. A stated improvement in the release does not substitute for this evaluation nor for the separate determination of any additional applicable regulatory requirements.
What drives the validation effort for Opcenter Execution Pharma?
Above all, different implementation paths, local device and automation integrations, custom extensions, and open validation evidence. A large number of similar steps is not inherently more resource-intensive than a few unclear handovers. Early consolidation of process knowledge, configuration details, and manufacturer documentation is essential. Only from this derived task list can a reliable planning basis be established; general cost or weekly resource commitments are not derived herein.
Must all previous validation evidence be replaced upon transition to the web client?
First assess the continued validity of their existing statements. Unchanged professional principles or appropriate standard evidence may remain applicable. Conditions affected by the change must be reviewed, such as documentation, access, equipment pathway, and error handling. Historical records and ongoing processes may also be impacted. A blanket, comprehensive replacement is no more justified than the unverified adoption of all previous results.
Sources and review date
Source date: 6 October 2026. Version-specific vendor basis: Opcenter Execution Pharma 2605, contribution dated 15 June 2026. Latest patch, customer license, and specific web coverage have not been verified. Matrices and order A-17 are internal planning aids only and do not represent completed product testing. Focus area: Human medicinal product GMP.
- Siemens: Opcenter Execution Pharma
- Siemens: What's new in Opcenter Execution Pharma 2605
- European Commission: EudraLex Volume 4
- European Commission: EU GMP Annex 11 – Computerised Systems
- European Commission: EU GMP Chapter 4 – Documentation
- EMA: ICH Q9(R1) – Quality Risk Management, Step 5, Corr.2
Sources checked: .
Protect the actually used MES paths intentionally.
We assist you in translating manufacturing specifications, client transfer, and automation handover into a traceable documentation strategy. Existing records are considered in accordance with their specific statements.
- Computer system validation →
Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

